ANNX Annexon, Inc. Stock Quote

ANNX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.96	Insider Own	-	Shs Outstand	28.46M	Perf Week	6.53%
Market Cap	1.11B	Forward P/E	-	EPS next Y	-1.70	Insider Trans	-	Shs Float	21.19M	Perf Month	38.07%
Income	-56.40M	PEG	-	EPS next Q	-0.44	Inst Own	95.70%	Short Float	3.10%	Perf Quarter	23.89%
Sales	-	P/S	-	EPS this Y	-107.10%	Inst Trans	4.56%	Short Ratio	4.29	Perf Half Y	17.51%
Book/sh	12.84	P/B	2.42	EPS next Y	54.90%	ROA	-37.80%	Target Price	35.33	Perf Year	-
Cash/sh	10.38	P/C	2.99	EPS next 5Y	38.60%	ROE	-649.20%	52W Range	15.33 - 38.01	Perf YTD	23.89%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-18.42%	Beta	-
Dividend %	-	Quick Ratio	41.60	Sales past 5Y	-	Gross Margin	-	52W Low	102.28%	ATR	3.14
Employees	38	Current Ratio	41.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.82	Volatility	13.28% 12.06%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.41	Prev Close	29.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	153.13K	Price	31.01
Recom	1.70	SMA20	7.45%	SMA50	16.83%	SMA200	23.23%	Volume	214,777	Change	6.89%

Jan-26-21

Initiated

Needham

Buy

$37

Aug-18-20

Initiated

JP Morgan

Overweight

$33

Aug-18-20

Initiated

Cowen

Outperform

Aug-18-20

Initiated

BofA Securities

Buy

$33

Mar-01-21 01:11PM	Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy Benzinga
07:00AM	Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy GlobeNewswire
Feb-08-21 07:00AM	Annexon Welcomes William H. Carson, M.D. to the Board of Directors GlobeNewswire +8.18%
Jan-12-21 07:00AM	Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics GlobeNewswire
Jan-05-21 07:00AM	Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference GlobeNewswire -5.52%
Dec-21-20 07:00AM	Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome GlobeNewswire -9.21%
Dec-11-20 01:15PM	Is ANNX A Good Stock To Buy Now? Insider Monkey
Nov-16-20 04:01PM	Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire
Nov-12-20 04:05PM	Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntingtons Disease Clinical Program GlobeNewswire
Oct-24-20 10:13AM	We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely Simply Wall St.
Sep-08-20 04:01PM	Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights GlobeNewswire
Jul-30-20 08:00AM	Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer GlobeNewswire
Jul-28-20 04:05PM	Annexon Announces Closing of Initial Public Offering GlobeNewswire

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience